Home › Funds › ArchPoint Investors › CLYM
ArchPoint Investors position in CLYM
CLIMB BIO INC · Health Care
ArchPoint Investors reported holding 132,900 shares of CLYM (CLIMB BIO INC) in its Q3 2026 13F filing — a position valued at US$1.5M, representing 0.32% of its reported portfolio and ranking #49 among its reported holdings. ArchPoint Investors has disclosed CLYM holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How ArchPoint Investors's CLYM position evolved
ArchPoint Investors first disclosed a stake in CLYM in Q4 2025 at 121,400 shares (US$486K). The position peaked in Q2 2026 at 128,900 shares, worth US$1.7M. Across 4 filings, ArchPoint Investors increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 132,900 shares valued at US$1.5M — an increase of 4,000 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 121.40K | $485.60K | New |
| Q1 2026 | 121.40K | $831.59K | Hold |
| Q2 2026 | 128.90K | $1.68M | Add |
| Q3 2026 | 132.90K | $1.52M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CLYM and 13F data
CLYM (CLIMB BIO INC) is a Health Care company. 73 other funds we track also report a position in CLYM — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$147.4M), BRAIDWELL LP (US$36.5M), Cormorant Asset Management, LP (US$27.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CLYM
- RA CAPITAL MANAGEMENT, L.P. 11.30M sh · $147.36M · Q2 2026
- BRAIDWELL LP 2.80M sh · $36.48M · Q2 2026
- Cormorant Asset Management, LP 2.11M sh · $27.46M · Q2 2026
- Redmile Group, LLC 1.23M sh · $15.99M · Q2 2026
- GREAT POINT PARTNERS LLC 1.00M sh · $13.04M · Q2 2026
- Affinity Asset Advisors, LLC 972.00K sh · $12.67M · Q2 2026
- ADAR1 Capital Management, LLC 822.65K sh · $10.73M · Q2 2026
- STEMPOINT CAPITAL LP 742.75K sh · $9.69M · Q2 2026
- Parkman Healthcare Partners LLC 563.48K sh · $7.35M · Q2 2026
- SUPERSTRING CAPITAL MANAGEMENT LP 521.08K sh · $6.79M · Q2 2026
- SPHERA FUNDS MANAGEMENT LTD. 483.75K sh · $6.31M · Q2 2026
- NAN FUNG TRINITY (HK) Ltd 360.65K sh · $4.14M · Q3 2026
More on ArchPoint Investors
FAQ
How long has ArchPoint Investors held CLYM?
ArchPoint Investors has disclosed CLYM holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is ArchPoint Investors's current position in CLYM?
As of Q3 2026, ArchPoint Investors holds 132.90K shares of CLYM (CLIMB BIO INC), valued at $1.52M, representing 0.32% of its reported portfolio and ranking #49.
Has ArchPoint Investors been buying or selling CLYM?
In the latest 13F filing (Q3 2026), ArchPoint Investors increased its position in CLYM. The position peaked in Q2 2026 at 128.90K shares.
Which other funds hold CLYM?
Other major institutional holders of CLYM include RA CAPITAL MANAGEMENT, L.P., BRAIDWELL LP, Cormorant Asset Management, LP, among 73 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.